| Description | Cefpiramide sodium (SM-1652; Wy-44635) is a Pseudomonas-active cephalosporin. It has a broad spectrum of antibacterial activity. |
| In vitro | Cefpiramide was moderately susceptible to hydrolysis by a variety of beta-lactamases from Gram-negative bacilli. Cefpiramide inhibited non-enterococcal streptococci, methicillin-susceptible staphylococci, Neisseria gonorrhoeae, N. meningitidis, and beta-lactamase-negative Haemophilus influenzae [1]. |
| In vivo | Cefpiramide inhibited staphylococci and streptococci and had appreciable activity against Streptococcus faecalis and Listeria moncytogenes [3]. Pharmacokinetic studies in mice showed that cefpiramide attained a peak serum concentration of 12 micrograms/ml and a serum half-life of 40 min, which are higher than attained by cefoperazone with values of 4 micrograms/ml and 18 min. These factors may have caused the combined cefpiramide-gentamicin therapy to result in significantly improved survival rates in mice as well as in higher bactericidal titers than the cefoperazone-gentamicin combination [2]. |
| Synonyms | 头孢匹胺钠, SM-1652, Wy-44635 |
| molecular weight | 635.63 |
| Molecular formula | C25H24N8NaO7S2 |
| CAS | 74849-93-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 39 mg/mL (61.36 mM) |
| References | 1. Barry AL, et al. Cefpiramide: comparative in-vitro activity and beta-lactamase stability. J Antimicrob Chemother. 1985 Sep;16(3):315-25. 2. Fu KP, et al. Therapeutic efficacy of cefpiramide and cefoperazone alone and in combination with gentamicin against pseudomonal infections in neutropenic mice. Chemotherapy. 1986;32(2):166-72. 3. Neu HC, et al. The in vitro activity and beta-lactamase stability of cefpiramide compared with other beta-lactam antibiotics. Diagn Microbiol Infect Dis. 1985 Nov;3(6):479-88. |